StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Fosamax by Year

Fosamax (alendronate, legacy pre-Organon spin-off) — International sales ($M) ($M)

Merck Fosamax: $205M in FY2018, down 12.8% from a year earlier. No newer figure appears in the documents we track.

Latest, FY2018
205
Period ended Dec 31, 2018
Change on a year earlier
-12.8%
235 in FY2017
History
3 years
Since FY2016
Sources
2
Documents cited below

Where the FY2018 figure comes from

“|| Fosamax | 209 | 241 | -13 | 4 | 6 | -33 | 205 | 235 | -13”

Source: Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedFosamax (alendronate, legacy pre-Organon spin-off) — International sales ($M) ($M)Year on yearSource
FY2018Dec 31, 2018205-12.8%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
FY2017Dec 31, 2017235-15.8%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
FY2016Dec 31, 2016279–Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗

Breakdown

What makes up fosamax

Cite this data

StockData. (2026). Merck Fosamax ($M), annual FY2016–FY2018 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-fosamax-intl

See every metric in the Merck KPI table. Data updated Oct 26, 2026.